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Haemophilia A is an X-linked recessive bleeding disorder charac-
terised by deficiency of coagulation factor VIII (FVIII).[1] The 
disorder can be classified according to procoagulant levels of FVIII: 
patients with severe haemophilia A have levels of <1 IU/dL, those with 
moderate disease 1 - 5 IU/dL, and those with mild disease 5 - 40 IU/
dL. The disorder mainly affects males, at a rate of 1 in 5 000 - 10 000 
worldwide.[1,2] The 2017 World Federation of Hemophilia survey[3] 
reported that 149 764 individuals were affected by haemophilia A 
globally, with only 1 848 reported in South Africa (SA).
Haemophilia A is underdiagnosed in SA, as in many other 
developing countries, owing to a lack of access to diagnostic expertise. [4] 
There is currently only one genetic testing facility, which services all 
the haemophilia A treatment centres in SA.[4] Genetic research on 
haemophilia is therefore limited in SA,[4] as evident from the FVIII 
gene (F8) variant database, to which SA has made no contribution.[5]
Genetic testing is of paramount importance in the comprehensive 
treatment plan for haemophilia A, since mutations in F8 are the cause 
of the disorder. Furthermore, F8 mutations may be associated with 
the development of FVIII inhibitors,[6] and variant detection allows 
for prenatal and carrier detection to enable genetic counselling of 
haemophilia A families.[7]
According to the literature, 45% of all severe haemophilia A 
cases are associated with an inversion in intron 22 (inv22) of F8.[8,9] 
Based on gene expression, an mRNA conventional inv22 polymerase 
chain reaction (PCR) screening method was developed to allow 
rapid detection of inv22.[10] This method assumes the presence of an 
additional exon, called exon 23c, contained in the inv22 mutant FVIII 
transcript.[11] Exon 23c was found to be spliced to exon 22 of F8 in 
unrelated haemophilia A patients.[10]
Objectives
To detect the presence of inv22 in the haemophilia A population of 
central SA and potential haemophilia A carriers.
Methods
Population group
Sixty-two participants were recruited from the haematology clinic 
at Universitas Academic Hospital in Bloemfontein and Robert 
Mangaliso Sobukwe Hospital in Kimberley. Twenty-seven families, 
represented by 34 patients with severe haemophilia A (FVIII 
<1  IU/dL), 3 with mild disease (FVIII 5 - 40 IU/dL), 18 potential 
haemophilia A carriers (mothers or sisters of known severe 
haemophilia A patients) and 7 healthy volunteers in Free State 
and Northern Cape provinces were included. The study group 
included all the severe haemophilia A patients and some of their 
family members who are actively treated at the Bloemfontein and 
Kimberley adult haemophilia state-operated clinics. In a recent 
unpublished MMed project, an internal file audit reported that these 
clinics had a total of 56 haemophilia A patients (M Roux, University 
of the Free State, unpublished data, 2018), of whom 25 with severe 
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and 1 with mild disease were regularly followed up at a haemophilia 
treatment clinic. All the actively treated patients were therefore 
recruited for the study, as well as some of the presumed inactive 
patients (not regularly attending a haemophilia treatment clinic), 
to make a total of 37  haemophilia A patients. With a population 
size of just over 2 million (2 040 707) males in the Free State and 
Northern Cape,[12] it would be expected that the two provinces would 
have ~204  haemophilia A patients. The relatively low number of 
56 patients may be an indication of the underdiagnosed state of the 
disorder or, less likely, that the prevalence of the disorder is much 
lower in the study area than elsewhere.
Three inv22 controls were included: an inv22-negative control 
(C1) and 2 unrelated inv22-positive controls (C2 and C3). These 
controls were also receiving active treatment for haemophilia A at 
the Bloemfontein state-operated clinic, and had previously been 
screened for inv22 using the Southern blot inv22 method. In all cases, 
the mutation status of the other study participants and the potential 
carriers was unknown.
Ethics approval was obtained from the Health Sciences Research 
Ethics Committee of the University of the Free State (ref. no. ECUFS 
166/2015) and the Free State (ref. no. FS_2015RP47_195) and 
Northern Cape (ref. no. NC_2015RP1_898) provincial departments 
of health.
RNA extraction and complementary DNA synthesis
Venous blood was collected in ethylenediaminetetra-acetic acid-
containing tubes. RNA was stabilised using RNALater solution 
(Ambion, Life Technologies, USA) and subsequently isolated with 
the RiboPure-Blood Kit (Ambion, Life Technologies, USA). A High-
Capacity RNA-to-cDNA kit (Applied Biosystems, USA) was used for 
complementary DNA (cDNA) preparation after RNA concentrations 
were measured using a Qubit 2.0 Fluorometer (Invitrogen, USA).
Inv22 screening
All the participants were screened with the published conventional 
inv22 PCR assay.[10] The Southern blot-confirmed inv22 patient 
samples were included in each run to serve as positive and negative 
inv22 controls. After gel electrophoresis, gel images were analysed to 
determine the inv22 genotypes of each study participant.
Additionally, a newly developed real-time PCR application was 
applied (Power SYBR Green Master Mix; Applied Biosystems, USA). 
The real-time PCR method allows for higher throughput of samples 
and requires less post-PCR involvement than a conventional PCR 
method, making it a more attractive option for high-throughput 
laboratories. Melt-profile analysis was performed to ensure real-time 
reverse transcriptase PCR reaction optimisation. Published primer 
pairs[9] were used and optimised for cDNA concentrations using the 
inv22 controls. For quality control purposes, a non-template sample 
and a Southern blot-confirmed positive inv22 control were included 
in each run, all reactions were performed in duplicate, and ROX-dye 
(Applied Biosystems, USA) served as internal control. Two separate 
real-time PCR reactions were prepared in duplicate, one containing 
the wild-type primers and the other the inv22 primers using the 2 × 
Power SYBR Green PCR Master Mix (Applied Biosystems, USA). 
Cycling conditions were 95°C for 10 minutes followed by 40 cycles 
at 95°C for 15 seconds and at 62°C for 1 minute. After that, melt-
curve analysis was conducted at 95°C for 1 minute and at 62°C for 
1 minute, followed by 40 cycles of melting starting at 60°C with 0.5°C 
increments (10 seconds for each increment) of heating. The real-time 
assay amplification curves and melt curves were then analysed to 
determine the accuracy of the assay in detecting the FVIII wild-
type and inv22 genotypes. The study participants were screened 
with the optimised real-time inv22 assay, and positive and negative 
controls were included in each run for quality control purposes. The 
amplification curves were analysed to determine the inv22 genotypes.
Sanger sequence analysis
Sanger sequencing was performed on all samples to confirm the 
PCR results and determine whether exon 23c is spliced to exon 
22 in all positive inv22 cases.[10] Following cDNA synthesis, the 
amplification product of each sample was treated with ExoSAP-
IT Express reagent (Affymetrix, USA). The purified PCR product 
consequently served as template for the sequencing reaction, using 
the BigDye Terminator v3.1 Kit (Applied Biosystems, USA), and 
impurities were removed using the ZR DNA Sequencing Clean-Up 
Kit (Zymo Research, USA). The sequence raw reads were analysed 
on the ABI Prism 3130 Genetic Analyser (Applied Biosystems, USA). 
The sequence of each sample was aligned (LALIGN) to the respective 
inv22 reference sequences. Sequence data were subsequently used to 
confirm the conventional and real-time inv22 PCR results.
Results
The inv22 results are summarised in Table 1. Ten (29.4%) of the 
haemophilia A participants were positive for inv22, 4 (22.2%) were 
carriers, and the rest of the participants were all inv22-negative. 
The inv22-positive samples displayed an expected mutant 132 base 
pair (bp) PCR fragment, and conversely the inv22-negative samples 
displayed an expected wild-type 260 bp fragment. Inv22 carriers 
displayed both the mutant and wild-type PCR fragments.[10]
The real-time inv22 assay detected 10 haemophilia A patients 
with inv22 (29.4%) and 3 inv22 carriers (16.7%). The remainder of 
the patients were all inv22-negative. The discrepancy in one carrier 
was attributed to possible sample-specific degradation, as there was a 
time lapse of more than a year between the conventional PCR and the 
real-time PCR. The same sample was used for the respective assays 
and was stored at –80°C. After repeated attempts, the real-time inv22 
PCR failed, which could have been due to cDNA degradation. The 
participant could not be reached for re-sampling.
Real-time inv22 PCR results for the study participants compared 
well with the inv22 controls. For the real-time inv22 assay, the 
inv22-negative control only had amplification curves for the wild-
type primer set, while the inv22-positive controls only displayed 
amplification curves for the mutant-type primer set. The melt-
curve analysis plots for all the controls indicated the absence 
Table 1. Summary of the inv22 results for the participants screened
Severe haemophilia A 
patients, n (%)
Moderate haemophilia 
A patients, n (%)
Mild haemophilia A 
patients, n (%)
Potential haemophilia 
A carriers, n (%)
Healthy controls, 
n (%)
Inv22-positive 10 (29.4) 0 0 4 (22.2) 0
Inv22-negative 24 (70.6) 0 3 (100) 14 (77.8) 7 (100)
Total, n 34 0 3 18 7
inv22 = intron 22 inversion.
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of primer dimer formation and multiple 
fragments. Fig. 1 displays the real-time 
inv22 PCR amplification curves for one of 
the haemophilia A carriers. Amplification 
occurred in both the wild-type and the 
mutant-type primer reactions, with both 
the inv22-positive controls and the negative 
control amplifying with the carrier sample.
Sanger sequencing results confirmed 
the PCR results for both assays. Patients 
who were positive for inv22 had exon 23c 
spliced to exon 22 of F8, and inv22 carriers 
had both wild-type exon 22 and exon 23c 
associated with inv22. Fig. 2 displays the 
sequence electropherogram for an inv22-
negative haemophilia A patient and an 
inv22-positive patient.
Discussion
Inv22 has been reported to affect 45% of 
all patients with severe haemophilia A and 
is the first mutation to be genotyped in 
cases of severe haemophilia A. We found 
inv22 in 29.4% of our haemophilia A 
study cohort in central SA, which was 
lower than the globally reported 45%.[8,9] 
The inv22-positive participants were all 
unrelated except for one pair of brothers, 
indicating that inv22 occurred in 9 of 
the 27 haemophilia A families (33.3%). 
The majority (80%) of the inv22-positive 
patients were black South Africans, with 
only 20% being white. This finding may 
suggest an ethnic contribution to inv22 
frequencies, but will have to be confirmed 
with a larger study cohort. Inv22 was found 
in 22.2% of the potential carriers. The lower 
prevalence of inv22 in our study population 
could be significant, considering that the 
majority of other studies have reported an 
inv22 prevalence of 45%. The sample size 
in this study was small, however, and to 
confirm such a hypothesis the remainder of 
the SA haemophilia A population will have 
to be screened for inv22. Interestingly, 24% 
of the severe haemophilia A patients had 
a history of FVIII inhibitor development, 
and of those patients, 33% had inv22. This 
finding is in keeping with the prediction 
that between 20% and 40% of patients with 
FVIII inhibitors have inv22.[13,14]
In this study, we modified a rapid and 
cost-effective conventional inv22 PCR RNA-
based screening method into a real-time 
inv22 PCR screening method that can be 
utilised by high-throughput laboratories that 
prefer real-time applications. The real-time 
inv22 PCR screening method seemed to 
be robust, as it compared well with the 
conventional inv22 PCR method and the 
results obtained with sequence analysis. A 
result discrepancy in one of the inv22 carrier 
participants was possibly attributed to the 
sample’s cDNA degrading during storage, 
as the conventional and real-time assays 
were done more than a year apart. We 
therefore recommend that the robustness of 
the real-time inv22 PCR screening method 
be confirmed with a further validation study 
to determine cDNA storage time stability 
before the assay is considered for diagnostic 
purposes.
Inv22 mutation status is unknown in most 
SA haemophilia A patients, with very few 
studies published on patient genotypes. [10] 
Possible carriers were included in the study, 
as carrier detection plays an important 
role in counselling haemophilia A families 
with regard to family planning and the 
risk associated with having a child with a 
bleeding disorder. In our setting, only severe 
haemophilia A patients actively attend our 
haemophilia clinics, and the population 
group may therefore be misrepresented with 
regard to mild and moderate haemophilia A 
patients. The literature and this study do not 
report mild and moderate haemophilia A 
patients with inv22.
Conclusions
Although a small population was 
investigated in this study, in our setting 
the haemophilia A group investigated 
was substantial in size considering the 
underdiagnosis of haemophilia A in SA,[4] 
and all actively treated severe haemophilia A 
patients in our setting were included. Future 
studies need to determine whether the 
inv22 prevalence is lower in the remainder 
of the SA haemophilia A population and 
what other causative mutations associated 
with haemophilia A are prevalent in this 
population.
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Fig. 1. Real-time intron 22 inversion polymerase chain reaction amplification plots for an intron 22 
inversion carrier: (A) amplification plot representing the wild-type primer reaction; (B) amplification 
plot representing the mutant-type primer reaction. The non-template control did not amplify in either 
of the reactions. (ΔRn = normalised fluorescent reported value minus the baseline signal.)
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F8 mutation detection has proved impor-
tant in haemophilia A treatment, with 
specific reference to F8 genotypes that are 
associated with FVIII inhibitor develop-
ment,[15] as well as genetic counselling.[4,6] 
This study lays the foundation for compre-
hensive genetic research to be conducted in 
the southern African haemophilia A popula-
tion, and we hope that it will contribute to 
better treatment and management plans for 
families affected by haemophilia A on the 
African continent in the future.
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Fig. 2. Sanger sequence electropherograms: (A) electropherogram depicting the mRNA sequence of an 
intron 22 inversion-negative sample, with exon 22 of F8 spliced to exon 23 of F8; (B) electropherogram 
depicting the mRNA sequence of an intron 22 inversion-positive sample, with exon 22 of F8 spliced to 
alternative exon 23c.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2. Sanger sequence electropherograms: (A) electropherogram depicting the mRNA sequence 
of an intron 22 inversion-negative sample, with exon 22 of F8 spliced to exon 23 of F8; (B) 
electropherogram depicting the mRNA sequence of an intron 22 inversion-positive sample, with 
exon 22 of F8 spliced to alternative exon 23c. 
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